Topic · 5 episodes

Health

Health in 2024 is being reshaped by precision medicine across several fronts. Onpode's coverage spans gene therapy for hereditary angioedema, a non-hormonal menopause treatment reducing hot flashes and mood symptoms, an oral GLP-1 pill delivering meaningful weight loss and blood sugar control, and the FDA's first targeted approval for PTEN-deficient prostate cancer. The through-line: treatments engineered for defined patient populations.

Frequently asked

What are the Phase 3 results for Intellia's lonvo-z gene therapy?

Intellia's lonvo-z posted strong Phase 3 results for hereditary angioedema treatment. The data marked a significant milestone for gene therapy in this rare genetic condition, suggesting lonvo-z could offer a durable intervention for patients managing hereditary angioedema.

Is there a menopause treatment that works without hormones?

A non-hormonal menopause treatment has shown in trials that it can reduce hot flashes, anxiety, and depression without the risks associated with hormone replacement therapy. This offers a meaningful alternative for people who cannot or prefer not to use HRT.

Can a pill replace injectable GLP-1 drugs for diabetes and weight loss?

A new GLP-1 diabetes pill has achieved significant weight loss and blood sugar control in clinical trials, suggesting an effective oral pill could be a viable alternative to injectable GLP-1 therapies for patients managing type 2 diabetes and obesity.

What is AstraZeneca's Truqap and what did the FDA approve it for?

AstraZeneca's Truqap received FDA approval as the first and only targeted treatment for PTEN-deficient prostate cancer. This approval represents a precision oncology advance, giving clinicians a specifically indicated option for a prostate cancer subgroup defined by PTEN loss.

Episodes